Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Microarrays & Multiplexing › Applied Biocode to Submit Gastrointestinal Pathogen Panel to FDA in Bid to Displace Luminex

Applied Biocode to Submit Gastrointestinal Pathogen Panel to FDA in Bid to Displace Luminex

Apr 20, 2017
|
Justin Petrone
Premium

NEW YORK (GenomeWeb) – Applied Biocode intends to have a panel for identifying 18 different gastrointestinal pathogens on the clinical market by the end of the year.

CEO Winston Ho said that the Santa Fe Springs, California-based molecular diagnostics company will soon commence clinical trials for the assay, called the Gastrointestinal Pathogen Panel, which runs on its barcoded magnetic bead-based multiplex BioCode MDx 3000 system, at five sites in the US.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Infectious Disease

  1. Roche SARS-CoV-2 Lateral Flow Antigen Test Could Meet Significant Demand

    Premium

  2. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

  3. Commercial Coronavirus Antibody Tests Show Wide Variation in Accuracy in New Study

  4. FDA Authorizes First COVID-19 Serology Test for Point-of-Care Use

  5. Oxford Immunotec T-Cell Test for SARS-CoV-2 Being Evaluated in Public Health England Study

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.